Background: Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper was to evaluate the available evidence and to assess the potential value of genotyping of UGT1A1∗28 and UGT1A1*6 in patients before starting treatment with irinotecan to reduce the risk of severe toxicity.
Methods: The literature was selected and assessed based on five pre-specified criteria: 1) the level of evidence for associations between UGT1A1 polymorphisms and irinotecan-induced severe toxicity, 2) clinical validity and utility of pre-therapeutic genotyping of UGT1A1, 3) safety and tolerability of irinotecan in carriers of UGT1A1 polymorphisms, 4) availability of specific dose recommendations for irinotecan in carriers of UGT1A1 polymorphisms, 5) evidence of cost benefits of pre-therapeutic genotyping of UGT1A1.
Results: On all five criteria, study results were favourable for pre-therapeutic genotyping of UGT1A1. A high level of evidence (level I) was found for a higher incidence of irinotecan-induced severe toxicity in homozygous carriers of UGT1A1*28 or UGT1A1*6. The clinical validity and utility of this genetic test proved to be acceptable. Dose-finding studies showed a lower maximum tolerated dose in homozygous variant allele carriers, and most of the drug labels and guidelines recommend a dose reduction of 25-30% in these patients. In addition, pre-therapeutic genotyping of UGT1A1 is likely to save costs.
Conclusion: Pre-therapeutic genotyping of UGT1A1 in patients initiating treatment with irinotecan improves patient safety, is likely to be cost-saving, and should, therefore, become standard of care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2020.09.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort.
Pharmacogenomics J
November 2024
Department of Clinical Chemistry, Catharina Hospital, Eindhoven, the Netherlands.
Article Synopsis
- Thiopurine drugs are crucial for managing inflammatory bowel disease (IBD), but they can cause side effects, particularly thiopurine-induced myelosuppression (TIM).
- A study in the Netherlands explored the frequency of the NUDT15*3 genetic polymorphism and its connection to TIM in IBD patients.
- Out of 988 patients, 1.3% had the NUDT15*3 variant; among those on thiopurines, 50% of carriers developed TIM compared to just 2.3% of non-carriers, indicating the importance of genetic testing before treatment.
Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy.
Strahlenther Onkol
September 2024
University Hospital for Radiation Oncology and Radiotherapy, University Hospital Tübingen, Tübingen, Germany.
Background: 5‑Fluoruracil (5-FU) and its oral prodrug capecitabine are mainstays in combined chemoradiotherapy regimens. They are metabolized by dihydropyrimidine dehydrogenase (DPYD). Pathogenic variants of the DPYD gene cause a reduction in DPYD activity, leading to possibly severe toxicities.
View Article and Find Full Text PDFPartial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping.
J Pharm Biomed Anal
October 2024
Laboratory of Chemical Biology, department of Biomedical Engineering, Eindhoven University of Technology, the Netherlands; Clinical Laboratory, Catharina Hospital Eindhoven, the Netherlands; Expert Center Clinical Chemistry Eindhoven, the Netherlands. Electronic address:
Fluorouracil is among the most used antimetabolite drugs for the chemotherapeutic treatment of various types of gastrointestinal malignancies. Dihydropyrimidine dehydrogenase (DPYD) genotyping prior to fluorouracil treatment is considered standard practice in most European countries. Yet, current pre-therapeutic DPYD genotyping procedures do not identify all dihydropyrimidine dehydrogenase (DPD)-deficient patients.
View Article and Find Full Text PDFNon-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report.
Curr Drug Saf
November 2023
Department of hepato-gastroenterology, Charles Nicolle Hospital, Tunis, Tunisia.
Background: The development of direct-acting antivirals directed against the Hepatitis C Virus has dramatically modified the therapeutic approach to chronic hepatic viral disease. Larger use of such drugs has also led to increasing reports about their adverse effects. This report aimed to describe a case of leucocytoclasic vasculitis following treatment based on the sofosbuvir/ledipasvir regimen with complete disappearance shortly after withdrawal in a 61-year-old patient treated for genotype 1 hepatitis C.
View Article and Find Full Text PDFImplementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
ESMO Open
April 2023
Department of Clinical Chemistry, Inselspital, Bern University Hospital & University of Bern, INO F, Bern, Switzerland. Electronic address:
Background: The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European Medicines Agency (EMA) recommended two methods for pre-treatment DPD deficiency testing in clinical practice: phenotyping using endogenous uracil concentration or genotyping for DPYD risk variant alleles. This study assessed the DPD testing implementation status in Europe before (2019) and after (2021) the release of the EMA recommendations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!